clinical trial · NCT04829318
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
Depressive Disorder, MajorEsketamineSSRI/SNRI
brief summary
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).
started
Apr 26, 2021
primary completion
Jul 22, 2024
completion
Jul 22, 2024
last updated
Sep 18, 2025
official title
Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol